Taizhou Beijin Biotechnology

Taizhou Beijin Biotechnology is a Chinese biopharmaceutical company focused on the development of innovative immunotherapy products, specifically leveraging natural killer (NK) cell technologies. Located in the China Medical City in Taizhou, the company specializes in the research and clinical transformation of universal CAR-NK cell therapies for the treatment of both solid tumors and hematological malignancies. Beijin Biotechnology has established a proprietary platform for the large-scale expansion and genetic modification of NK cells, aiming to provide off-the-shelf cellular immunotherapy solutions. Their pipeline includes several candidates targeting common oncology markers such as CD19 and mesothelin.